Sickle Cell Awareness Group and Canadian Blood Services host Black History Month donation event

City TV News-Toronto Watch

Dr. Jacob Pendergrast CTV interview for Canadian Blood Services Black History Month Drive

CTV News-Toronto Watch's coverage of the event

The event included information sessions to learn more about sickle cell and blood donation

Articles

Discover other Patient & Caregivers Articles

SCAGO

Health Canada Grants Marketing Authorization of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY®

The Sickle Cell Awareness Group of Ontario (SCAGO) is pleased with the news of CASGEVY (Exagamglogene Autotemcel) receiving marketing authorization for the treatment of Sickle Cell and Thalassemia disorders in Canada.

SCAGO

Health Canada Grants Marketing Authorization of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY®

SCAGO

Health Canada Grants Marketing Authorization of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY®

Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA® (voxelotor) From Worldwide Markets

Pfizer Inc. announced today that it is voluntarily withdrawing all lots of OXBRYTA ® (voxelotor) for the treatment of sickle cell disease (SCD) at this time, in all markets where it is approved.

Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA® (voxelotor) From Worldwide Markets

Pfizer Inc. announced today that it is voluntarily withdrawing all lots of OXBRYTA ® (voxelotor) for the treatment of sickle cell disease (SCD) at this time, in all markets where it is approved.

Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA® (voxelotor) From Worldwide Markets

Pfizer Inc. announced today that it is voluntarily withdrawing all lots of OXBRYTA ® (voxelotor) for the treatment of sickle cell disease (SCD) at this time, in all markets where it is approved.